Korean pharmaceutical and biotech companies have jumped into the development of new drugs for pancreatic cancer, which is categorized as refractory cancer. Prestige Biopharma, New Cancer Cure Bio (NCC-Bio), LigaChem Biosciences, and Aptamer Sciences are conducting clinical trials to challenge the field. These companies plan to investigate the commercialization potential of their candidates through antibody-drug conjugates (ADCs), targeted anti-cancer agents, and new antibody drugs.

New ADC drugs target TROP2 for treating pancreatic cancer

According to industry sources on August 29th, Aptamer Sciences applied for a patent for its 'Aptamer-Drug Conjugate (ApDC)' and commenced treatmen